Description Drostanolone Enanthate Strength: 200 mg/ml Molecular Formula: C27H44O3 Molecular Weight: 416.64 g/mol Active Ingredient: Drostanolone enanthate CAS number: 472-61-145 Dosage Form: Injectable, oil base sterile solution Route: Injection Market Status: Prescription Company: Hilma Biocare DESCRIPTION Drostanolone Enanthate 200 is a synthetic derivative of dihydrotestosterone, producing an anabolic effect and promoting protein synthesis as well as creating positive nitrogen balance in humans. Since it is a derivative of dihydrotestosterone, drostanolone does not aromatize to estrogens. Drostanolone Enanthate 200 has significant anabolic and androgenic properties promoting an increase in Te strength and growth of muscle tissue while acting as an estrogen antagonist. The combination of a short-acting propionate ester with a longacting enanthate ester pro- duces rapid increases in serum drostanolone levels with a Sustained duration of 5-8 days. CLINICAL PHARMACOLOGY Anabolic steroids are synthetic derivatives of testosterone. Certain clinical effects and adverse reactions demonstrate the androgenic properties of these drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are thus similar to those of male sex hormones. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes. During exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone (LH). At large doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH). Drostanolone attaches to androgen receptors; increasing nitrogen retention and protein synthesis. Drostanolone acts on DHT modulated pathways as well, Drostanolone is a potent estrogen antagonist and does not aromatize to estrogen, limiting expression of side effects often linked to estrogen such as water retention, gynecomastia, and some types of high blood pressure. Drostanolone undergoes hepatic metabolism with a half- life of 2-3 days after separation of the ester. INDICATIONS To rapidly restore muscle tissue atrophied during recovery from a traumatic injury. To offset muscle catabolism in patients with a wasting syndrome.DA To treat certain types of anemia which are non-responsive to first line agents. Oestrogen antagonist in treatment of breast cancer. CONTRAINDICATIONS Not indicated for women, children, or the elderly. Women who are pregnant or may become pregnant because of possible masculinization of the fetus. Patients with nephrosis or the nephrotic phase of nephritis. Patients with hypercalcemia. Patients suffering from testicular cancer, prostate cancer, breast cancer, liver damage, kidney damage, stroke, high blood pressure, heart disease or respiratory problems. PRECAUTIONS Elevated liver enzymes and in rare cases hepatic liver dysfunction may occur. Periodic liver function should be monitored for changes including serum bilirubin, AST, ALT, and AP. Edema may be increased in patients on concurrent adrenal cortical steroid or ACTH therapy. Anabolic steroid hormones may increase low-density lipoproteins (LDL) and decrease high density lipoproteins (HDL).Lipids levels generally return to normal upon discontinuation of treatment. Anabolic steroids may reduce clotting factors II, V, VII, and X, and may increase prothrombin time (PT). Patients should be instructed to report any use of warfarin and any irregular bleeding. ADVERSE REACTIONS Male: Gynecomastia, excessive frequency and duration of penile erections, oligospermia. Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia. Fluid/electrolyte Disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis. Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anticoagulant therapy. Nervous System: Changes in libido, aggression, headache, anxiety, depression, and generalized paresthesia. Metabolic: reduced glucose tolerance, increased creatinine clearance, and inhibition of gonadotropin secretion. Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea. PATIENT MONITORING Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests – AST/ALT Prostatic specific antigen – PSA, Testosterone: total, free, and bioavailable. Dihydrotestosterone & Estradiol. Male patients over 40 should undergo a digital rectal luoR examination and evaluate PSA prior to androgen use. mo Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with difficulty in urination or with changes in voiding habits. DOSAGE AND ADMINISTRATION Adult male: 100 – 150 mg injected IM every 3-5 days for a duration of 4-8 weeks. PRESENTATION Drostanolone Enanthate 200 mg/ml, 10 ml multiple dose vial. STORAGE Store in a cool dry place between 15 -25°C. Protect from light.